Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by HighSkies2019on Feb 24, 2021 9:09pm
330 Views
Post# 32654761

Maybe FDA Approval ???

Maybe FDA Approval ???it sounds like they have already been testing R107 .. maybe we are gonna get an FDA pass...not very often you get a nr couple days b4 being unhalted ...Rob did say in one of his little love letters that he anticipated the news would eliminate shorting ...I pulled this out Its a pretty remarkable drug. It has a risk profile that is minimalDr. Lorenzo Berra, the critical-care specialist at Massachusetts General Hospital Dr. Lorenzo Berra, the critical-care specialist at Massachusetts General Hospital who is overseeing an international trial of nitric oxide in treatment of COVID-19 stated, Its a pretty remarkable drug. It has a risk profile that is minimal. Dr. Keith Scott, principal investigator of the Louisiana component of the Mass General trial stated that, We have tremendous confidence this therapy will alter the devastating effects of COVID-19 If results show promise, and since this gas is already FDA-approved, widespread use could begin immediately. Ake Lundkvist, a professor at Uppsala University, who led the Uppsala study, stated, To our knowledge, nitric oxide is the only substance shown so far to have a direct effect on SARS-CoV-2
<< Previous
Bullboard Posts
Next >>